GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Geron Corporation
Shares of Geron, a biotech company, soared following the FDA approval of its blood disorder drug. The price chart is a classic story of years of research culminating in success, which now awaits confirmation through commercial sales.
Share prices of companies in the market segment - Oncology platforms
Geron Corporation (GERN) is a biotech company specializing in the development of telomerase inhibitor-based therapeutics for the treatment of hematologic cancers. We classify it as an "Oncology Platform." The chart below reflects the dynamics of this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Geron is a biotech company pioneering the development of telomerase-targeted drugs for the treatment of blood cancer. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Geron shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
GERN - Daily change in the company's share price Geron Corporation
Shares of Geron, a biotech company, are experiencing extreme volatility. Change_co measures the market reaction to news of the approval and commercial launch of its first drug. This metric is a critical component of formulas on System.GURU.Markets that assess binary risks and potential in biotech.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Geron Corporation is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with GERN, which focuses on blood cancer treatment, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Geron is a biopharmaceutical company specializing in telomerase-targeted drugs for the treatment of cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Geron shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Geron Corporation
Geron is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Geron Corporation is a late-stage biotech developing a first-in-class telomerase inhibitor therapy for the treatment of blood cancers. Its stock price reflects the enormous potential of its breakthrough technology and the regulatory risks associated with bringing this new drug to market.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Geron is a biotech company whose fate since its IPO has depended on the success of its drugs. Its stock price is completely disconnected from economic cycles. Its chart reflects scientific events—news about clinical trials and regulatory decisions—rather than macroeconomic data, making it a high-risk science bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Geron Corporation
The value of Geron, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials and approval of its blood disorder drug, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Geron Corporation is a biotech company, a pioneer in telomerase, developing a therapy for blood cancer. Its shares are betting on the success of its leading drug, imetelstat. The chart below reflects the overall sentiment in the oncology platform sector, where every trial result changes everything.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Geron Corporation is a biotech company focused on treating blood cancer. Its only drug is in late-stage development. The company's stock is a binary bet on its approval and commercial success. Its performance is determined entirely by regulatory news and is independent of the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Geron Corporation
For Geron, a biotech company focused on blood cancer treatment, weekly performance has been extremely volatile. News of clinical trial results for its only key drug and FDA decisions are the main factors driving sharp price surges.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Geron shares, like those of the entire oncology biotech sector, are driven by sector-wide news and sentiment. Breakthroughs in blood cancer treatments or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Geron, like many biotech companies, can exhibit dynamics completely unrelated to the market. Positive clinical trial data can cause its shares to skyrocket even on the day the S&P 500 is plunging. The chart will show these moments of "living in its own world."
Market capitalization of the company, segment and market as a whole
GERN - Market capitalization of the company Geron Corporation
Geron's market capitalization chart is a financial valuation of a biotech company that spent decades developing a first-in-class telomerase inhibitor for the treatment of blood cancer. It reflects the long and arduous path to FDA approval. Its recent growth is a story of how scientific persistence can finally bear fruit and earn investor recognition.
GERN - Share of the company's market capitalization Geron Corporation within the market segment - Oncology platforms
Geron Corporation is a pioneering biotech company in the telomerase field, developing a drug for the treatment of blood cancers. Its market share is based on its unique scientific approach. The chart shows how the market views the potential of its lead candidate, which could become a new standard of treatment.
Market capitalization of the market segment - Oncology platforms
Geron Corporation is a pioneer in developing telomerase therapy for the treatment of blood cancer. The chart below shows the overall market capitalization of the oncology platform sector. Its dynamics reflect the long and arduous journey from a scientific idea to an approved drug. Geron's story is one of perseverance in biotech.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible in the chart are seeking ways to combat aging. Geron Corporation is developing telomere-targeted therapy for blood cancer. Its market cap represents an extremely risky bet on its innovative scientific approach to oncology and aging.
Book value capitalization of the company, segment and market as a whole
GERN - Book value capitalization of the company Geron Corporation
Geron's book value is capital used to combat aging at the cellular level. While in development, the company is using its financial assets to support clinical trials of its lead drug, a telomerase inhibitor targeting blood cancer.
GERN - Share of the company's book capitalization Geron Corporation within the market segment - Oncology platforms
Geron Corporation, a biotech company, is in the late stages of developing its blood cancer drug. Its share of the sector's assets, consisting of R&D capacity, is small. Its entire value lies in the potential of a single, yet highly significant, drug.
Market segment balance sheet capitalization - Oncology platforms
Geron Corporation is a biotechnology company. The pharmaceutical industry, as the graph shows, is both knowledge- and capital-intensive. Geron focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Geron Corporation is a biotechnology company that has been researching telomerase for decades. Its book value is the capital it invests in its lead drug, idatelsedate, for the treatment of blood disorders.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Geron Corporation
Geron Corporation is a biotech company. Its entire market capitalization is a premium to its cash flow. This premium is a bet that its blood disorder treatment, decades in development, will finally succeed.
Market to book capitalization ratio in a market segment - Oncology platforms
Geron Corporation is a biotech company specializing in the development of telomerase-inhibiting drugs for the treatment of cancer. Its value is almost entirely dependent on the success of its lead drug. The chart shows the market's high valuation of its scientific potential compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Geron Corporation is a biotechnology company focused on developing telomerase inhibitors for the treatment of blood cancers. Compared to the average market valuations shown in this chart, its valuation is based on the potential of its lead drug candidate, which recently received FDA approval, a key milestone for the company.
Debts of the company, segment and market as a whole
GERN - Company debts Geron Corporation
Geron Corporation is a biotechnology company specializing in the development of telomerase-targeted drugs for the treatment of cancer. Decades of research and clinical trials require a constant influx of capital. This chart shows how the company funds its long-term scientific mission to create a fundamentally new class of drugs.
Market segment debts - Oncology platforms
Geron Corporation is a biotech company that has been developing a telomerase-based drug for decades. As it approaches potential approval of its first drug, the company is incurring significant expenses. This chart shows its financial position at this crucial stage in its history.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Geron Corporation
Geron Corporation is a biotech company specializing in blood cancer treatments. This chart shows its financial structure. For a company whose primary asset is a promising development but lacks stable sales, any debt is a significant risk. Its future depends on regulatory approval and its ability to raise equity capital.
Market segment debt to market segment book capitalization - Oncology platforms
Geron Corporation is a biotech company focused on developing telomerase inhibitors for the treatment of cancer. This is an innovative but highly risky approach. The chart shows the overall debt burden in the sector, providing context for understanding how Geron finances its lengthy and expensive clinical trials.
Debt to book value of all companies in the market
Geron Corporation is a biotech company focused on developing drugs for blood cancer. After decades of research, it is on the verge of bringing its first drug to market. This chart shows that the company will likely use equity rather than debt to finance this final, most expensive stage.
P/E of the company, segment and market as a whole
P/E - Geron Corporation
This chart shows the valuation of Geron, a biotech focused on treating blood cancer. The company doesn't have consistent profitability, so the P/E ratio isn't relevant. Its value is determined by investors' faith in the success of its lead drug candidate, which is a binary bet on clinical trial results.
P/E of the market segment - Oncology platforms
Geron Corporation is a late-stage biotech company specializing in telomerase inhibitors for the treatment of blood cancers. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with Geron's innovative platform.
P/E of the market as a whole
Geron Corporation is a biotech company focused on developing telomerase-targeted drugs for the treatment of blood cancers. Its valuation is entirely dependent on the success of its lead drug candidate. Overall market sentiment, reflected in this chart, is irrelevant compared to clinical trial results and regulatory decisions.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Geron Corporation
Geron Corporation is a biotechnology company specializing in the development of telomerase-inhibiting drugs for the treatment of cancer. Its valuation is dependent on the success of its lead drug candidate. This chart demonstrates investor confidence in Geron's scientific platform and the commercial potential of its blood cancer treatments.
%20P%2FE%20Geron%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Geron-Corporation&v=1772663799538 "Chart of the company's future (projected) P/E Geron Corporation")
Future (projected) P/E of the market segment - Oncology platforms
Geron Corporation is a late-stage biotech company specializing in telomerase inhibitors for the treatment of blood cancers. The chart reflects average expectations for the oncology segment. GERN's position relative to this benchmark reflects investors' long-standing bet that their unique scientific approach will finally bear fruit in the form of an approved drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772663799585 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Geron Corporation is a late-stage biotech developing a therapy for blood cancer. Its valuation is highly dependent on regulatory decisions and the successful launch of its drug. This overall market sentiment graph is important because it determines how willing investors are to support the company during the final, most expensive stage.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772663799612 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Geron Corporation
Geron Corporation is a biotechnology company developing and commercializing telomerase inhibitor-based drugs for the treatment of blood cancers. Its financial performance reflects a long R&D pipeline. Future revenue is contingent on FDA approval and the successful launch of its lead drug.
Profit of companies in the market segment - Oncology platforms
Geron Corporation is a biotechnology company specializing in the development of telomerase inhibitor-based drugs for the treatment of oncology, particularly myelodysplastic syndrome. This chart shows the overall profitability of the oncology platform sector, reflecting investment interest and scientific progress in the development of new classes of anti-cancer drugs.
Overall market profit
Geron Corporation is a biotechnology company specializing in the development of telomerase-targeted drugs for the treatment of cancer. Its future depends solely on the results of clinical trials. The overall economic situation, reflected in this chart, has little impact on its operational performance but is important for attracting long-term capital from investors.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Geron Corporation
Geron Corporation is a biotechnology company focused on developing telomerase inhibitors for the treatment of blood cancers. Its future depends entirely on the success of its lead drug candidate. This chart reflects analysts' speculative expectations regarding the clinical results and commercial potential of this new therapeutic approach.
%20profit%20of%20the%20company%20Geron%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Geron-Corporation&v=1772663799911 "Graph of future (projected) profit of the company Geron Corporation")
Future (predicted) profit of companies in the market segment - Oncology platforms
Geron Corporation is a biotech company focused on developing telomerase inhibitors for the treatment of oncology. Its lead drug targets myelodysplastic syndromes. The company's future depends on the success of clinical trials. This chart reflects forecasts for the biotech sector, providing context for assessing Geron's potential and risks in oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772663799955 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Geron Corporation is a biotechnology company specializing in cancer treatment. Its value and future are determined solely by the results of clinical trials and the potential of its scientific developments. The overall macroeconomic indicators presented in this chart are irrelevant.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772663799991 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Geron Corporation
Geron Corporation is a biotech company focused on developing telomerase-inhibiting drugs for cancer treatment. Currently in late-stage clinical trials, it is attracting significant attention. This chart reflects investors' binary bets on the approval of its first drug and its potential to become a blockbuster.
P/S market segment - Oncology platforms
Geron Corporation is a biotechnology company pioneering the development of telomerase inhibitor-based therapies for the treatment of blood cancers. Future revenue depends on the success of its lead drug. This oncology chart reflects investor expectations for Geron's potential to offer a novel mechanism of action for the treatment of myelodysplastic syndromes.
P/S of the market as a whole
Geron Corporation is a biotechnology company focused on developing and commercializing telomerase-inhibiting drugs for the treatment of hematological malignancies. This market revenue valuation chart helps understand how investors value the company's potential for a first-in-class drug for the treatment of certain blood cancers.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Geron Corporation
Geron Corporation is a late-stage biotechnology company focused on telomerase-targeted therapies for the treatment of hematological malignancies. This chart shows how the market assesses the future commercial potential of its lead drug candidate, placing a premium on its regulatory approval and market success.
%20P%2FS%20Geron%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Geron-Corporation&v=1772663800162 "The graph of the company's future (projected) P/S Geron Corporation")
Future (projected) P/S of the market segment - Oncology platforms
Geron Corporation is a late-stage biotechnology company focused on developing a telomerase inhibitor for the treatment of hematological malignancies. The company's valuation reflects high expectations for its lead drug, which could become a new standard of care for patients with myelodysplastic syndromes.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772663800236 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Geron Corporation is a biotech company pioneering the development of telomerase-based therapies for the treatment of cancer. Its valuation is based on the potential of a single key drug. In the overall revenue growth picture illustrated by the chart, Geron represents a high-risk biotech.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772663800299 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Geron Corporation
Geron Corporation is a biotechnology company developing drugs for the treatment of blood cancers. Its lead candidate, isetelomerstat, is in late-stage development. The revenue reflected in this chart likely stems from licensing agreements, as the company has not yet achieved commercial sales.
Sales of companies in the market segment - Oncology platforms
Geron Corporation (GERN) is a biotechnology company pioneering telomerase research. Its lead drug, ielstat, is being developed for the treatment of myelodysplastic syndromes and other hematological malignancies. This chart shows revenue in the oncology sector, where Geron's breakthrough research could lead to the creation of a new class of anticancer drugs.
Overall market sales
Geron Corporation is a late-stage biotech company focused on blood cancer treatments. Its future depends on the approval and commercial success of its lead drug. The overall economic situation, reflected in this chart, impacts the ability of the healthcare system, particularly Medicare, to pay for new, expensive cancer drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Geron Corporation
Geron Corporation is a biotechnology company focused on developing telomerase inhibitors for the treatment of blood cancers. Its flagship drug, imetelstat, is in late-stage development. This chart reflects analysts' forecasts for future sales, which essentially assess the likelihood of approval and commercial success for this innovative drug.
%20sales%20of%20the%20company%20Geron%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Geron-Corporation&v=1772663800659 "Schedule of future (projected) sales of the company Geron Corporation")
Future (projected) sales of companies in the market segment - Oncology platforms
Geron Corporation is a biotech company developing telomerase inhibitor-based therapies for the treatment of blood cancers. This graph shows the potential future revenue of their lead drug, imetelstat. This is an analyst's perspective on the commercial prospects of this innovative approach to cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772663800723 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Geron Corporation is a late-stage biotech focused on developing telomerase inhibitors for the treatment of blood cancers. Its value is almost entirely dependent on the success of its lead drug. This chart, reflecting sentiment in the biotech sector, influences investor valuations of the company ahead of key regulatory decisions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772663800831 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Geron Corporation
Geron Corporation is a biotechnology company specializing in the development of telomerase inhibitors for the treatment of blood cancers. Its sole drug, imetestat, is in late-stage clinical trials. The chart shows the company's financial health, with its entire future profitability dependent on the success and commercialization of this single, yet potentially breakthrough, drug.
Market segment marginality - Oncology platforms
Geron Corporation is a biotechnology company specializing in the development of telomerase inhibitors for the treatment of cancer. Its lead candidate, imetelstat, is designed for the treatment of myelodysplastic syndromes. This graph depicts the company's path to profitability, which is contingent on the approval and success of its drug.
Market marginality as a whole
Geron Corporation is a biotechnology company specializing in the development of telomerase-targeted drugs for the treatment of cancer. It is in late-stage clinical trials. This total return chart reflects the investment climate. Positive economic conditions facilitate the significant capital required to bring the drug to market.
Employees in the company, segment and market as a whole
Number of employees in the company Geron Corporation
Geron Corporation is a biotech company, a pioneer in telomerase, developing drugs for blood cancer. As its lead drug moves toward approval, its team is expanding. This timeline shows how the company is hiring specialists to prepare for commercial launch.
Share of the company's employees Geron Corporation within the market segment - Oncology platforms
Geron Corporation is a late-stage biotechnology company focused on treating blood cancer. As it nears potential market launch, the company is expanding its staff. This timeline reflects its transition from a purely research organization to a commercial-ready company, which requires new competencies.
Number of employees in the market segment - Oncology platforms
Geron Corporation is a biotech company, a pioneer in telomerase, developing drugs to treat blood cancers. This chart, showing the oncology platform sector, illustrates the diversity of approaches to cancer treatment. For Geron, with its unique focus, growth in this area means both recognition of new mechanisms and competition for investor attention.
Number of employees in the market as a whole
Geron Corporation is a late-stage biopharmaceutical company specializing in hematological malignancies. Its expansion is driven by the progress of its lead drug candidate through clinical trials and commercialization. It represents a high-risk, innovative segment of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Geron Corporation (GERN)
Geron Corporation is a biopharmaceutical company specializing in the development of telomerase-targeted drugs for the treatment of blood cancers. Its business is entirely dependent on the success of clinical trials. This metric reflects how the market perceives the potential of its lead drug. A high value indicates investor confidence in the potential of a potential blockbuster.
%20of%20the%20company%20Geron%20Corporation%20(GERN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Geron-Corporation-GERN&v=1772663801134 "Chart of market capitalization per employee (in thousands of dollars) of the company Geron Corporation (GERN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Geron Corporation is a biotech company focused on developing telomerase-inhibiting drugs for cancer treatment. Its market cap reflects its unique scientific approach. The chart shows the enormous future value the market is placing on its research team.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772663801153 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Geron Corporation is a biotechnology company developing telomerase inhibitor-based drugs for the treatment of blood cancers. The chart reflects the company's estimated scientific potential, which is in late-stage clinical trials. Its entire value is based on the hope of approval and future sales of its lead drug candidate.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772663801165 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Geron Corporation (GERN)
Geron Corporation is a biotech company focused on oncology, specifically telomerase inhibitors. They have a late-stage drug (Imetelstat). This graph likely shows negative values—the "capital burn" per scientist. It reflects the amount of R&D investment required to bring their lead candidate to market.
%20Chart%20Geron%20Corporation%20(GERN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Geron-Corporation-GERN&v=1772663801185 "Company Profit Per Employee (in thousands of dollars) Chart Geron Corporation (GERN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Geron Corporation (GERN) is a biotech company that has been working on telomerase for decades. Their drug, Imetelstat, was recently approved by the FDA for the treatment of blood disorders (MDS). This milestone marks the culmination of a long R&D process and the beginning of a very expensive commercialization process.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772663801223 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Geron Corporation is a biotech company focused on developing telomerase inhibitors (Imetelstat) for the treatment of blood cancers. It is a late-stage R&D company and is not profitable. This chart is important to understand that in the innovative oncology sector, an employee's value is measured not by current profits, but by the potential for a blockbuster drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772663801242 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Geron Corporation (GERN)
Geron Corporation is a biotech company focused on developing telomerase inhibitors for the treatment of blood cancers. Being in late-stage clinical trials, its revenue per employee is minimal. The graph reflects this phase, and its future sharp growth depends on regulatory approval and the commercial launch of its lead drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Geron-Corporation-GERN&v=1772663801259 "Sales chart per company employee Geron Corporation (GERN)")
Sales per employee in the market segment - Oncology platforms
Geron (GERN) is a biotech company focused on developing telomerase inhibitors (Imetelstat) for the treatment of blood cancer. This chart shows the average revenue per employee in the segment. It helps assess how effectively Geron is commercializing its drug following its recent FDA approval.
Sales per employee for the market as a whole
Geron (GERN) is a late-stage biotech focused on telomerase inhibitors for the treatment of blood cancers. Their key drug (Imetelstat) is close to approval. This metric, which is currently likely low (no sales), is a benchmark. If approved, it should soar, demonstrating the commercial payoff of years of R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Geron Corporation (GERN)
Geron (GERN) is a biotech company that has been working on telomerase inhibitor-based therapies for decades. Its sole drug, Imetelstat, recently received approval. This chart shows short interest. High values reflect investor doubts about the commercial success of the long-awaited drug: the market may be concerned about its side effects or narrow niche use. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Geron-Corporation-GERN&v=1772663801411 "Short Shares Chart for the Company Geron Corporation (GERN)")
Shares shorted by market segment - Oncology platforms
Geron is a biotech company, a pioneer in the field of telomerase. It is developing a drug (Imetelstat) for the treatment of blood cancer (MDS). This chart shows the general sentiment in the sector. It reflects investor skepticism toward biotech companies that have been pursuing a single drug for decades.
Shares shorted by the overall market
Geron (GERN) is a biotech company that has been working for decades on a single drug (Imetelstat) for the treatment of blood cancer. It has been a long and grueling saga. This chart illustrates the skepticism that has accumulated over the years. Bears are betting that the drug, even if approved, will not become a commercial success, or that its side effects will limit its use, failing to live up to decades of expectations.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Geron Corporation (GERN)
Geron Corporation is a biotech company focused on anti-aging and anti-cancer drugs (telomerase). The stock is highly speculative. This GERN chart can soar above 70 on positive R&D news or FDA approvals. Below 30 is often associated with research setbacks, delays, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Geron-Corporation-GERN&v=1772663801589 "RSI 14 indicator chart for the company's stock Geron Corporation (GERN)")
RSI 14 Market Segment - Oncology platforms
Geron (GERN) is a biotech whose fate depends almost entirely on a single drug (Imetelstat) for the treatment of blood cancer. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is GERN's wild volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
For Geron, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GERN (Geron Corporation)
Geron (GERN) is a biotech company focused on developing telomerase inhibitors for the treatment of blood cancers. This chart shows the average 12-month forecast. It reflects analysts' confidence in the commercial success of its key drug, Imetelstat, following FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GERN-Geron-Corporation&v=1772663801791 "A chart showing analyst consensus forecasts for the expected stock price. GERN (Geron Corporation)")
The difference between the consensus estimate and the actual stock price GERN (Geron Corporation)
Geron Corporation is a biotechnology company focused on developing telomerase inhibitors for the treatment of blood cancer (myelodysplastic syndrome). This chart shows the gap between the market's current valuation of GERN and analysts' perceptions of its value. This reflects their opinion of the commercial potential of their lead drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GERN-Geron-Corporation&v=1772663801876 "A chart showing the difference between the consensus forecast and the actual stock price. GERN (Geron Corporation)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Geron is a biotech company that has spent decades developing its sole drug, Imetelstat (a telomerase inhibitor), for the treatment of rare blood cancers. This chart shows analysts' overall expectations across the oncology sector, reflecting whether experts believe this long-awaited drug will be commercially successful.
Analysts' consensus forecast for the overall market share price
Geron Corporation is a biotechnology company pioneering telomerase inhibitors for the treatment of blood cancer (myelodysplastic syndrome, MDS). This is a highly specialized oncology category. This chart shows overall market sentiment. For Geron, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences the funding and commercialization of their research. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Geron Corporation
Geron (GERN) is a biotech company that has been working for decades toward one goal: telomerase inhibitors. Their first drug (Imetelstat) targets rare blood disorders (MDS). This graph represents the R&D bet of a lifetime. Its valuation reflects the market's belief that their first drug will finally receive FDA approval and become a commercial success after a very long journey.
AKIMA Market Segment Index - Oncology platforms
Geron (GERN) is a biotech pioneer in telomerase; after decades of R&D, the company finally received approval for its first drug (Imetelstat) for a rare blood disorder (MDS). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough R&D platform (GERN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Geron is a biopharmaceutical company specializing in blood cancer treatment. It recently received approval for its first drug, Rytelo. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this transition from R&D to sales compares to the overall economic trends affecting biotech.
